期刊文献+

结肠癌血管生成相关因子的表达及其意义的研究 被引量:2

Expression of Angiogenesis Stimulators in Human Colon Cancer
原文传递
导出
摘要 目的研究VEGF配体及其受体在结肠癌发生、发展、转移中的作用,探讨VEGF家族与结肠癌各个时期病理特征的关系。方法在肿瘤标本,癌旁及正常组织标本中,用半定量RT-PCR方法,测定各种标本中VEGF各配体及VEGF受体表达,以研究它们在结肠癌进程中的作用。同时用免疫组化方法,对上述因子进行研究。结果 (1)与正常组织相比,VEGF-A、VEGF-C在肿瘤组织中显著升高(P<0.01);VEGF-B在肿瘤和正常组织中表达相近,而VEGF-D在肿瘤组织中显著降低;(2)VEGF-A、VEGF-B、VEGF-C在有淋巴结转移的肿瘤中明显升高(P<0.01);VEGF-D在有淋巴结转移的肿瘤中下降,但没有统计学差异。(3)VEGFR-1与Duke's分期,淋巴结转移显著相关(P<0.01);VEGFR-2与淋巴结转移显著相关(P<0.01);VEGFR-3与临床病理特征均不相关;VEGFR-1在肿瘤组织比正常组织升高(P<0.01),但VEGFR-2和VEGFR-3表达在肿瘤进程中没有显著升高。结论 VEGF-A、VEGF-B与结肠癌早期发展过程相关,VEGF-C、VEGFR-1与结肠癌进展过程相关,并和VEGF-D、VEGFR-2共同参与转移过程。 Objective Our aims were to identify which VEGF family rnelnbers are involved during colon cancer progTession, and to correlate expression with elinieopathological parameters in different cancer stage. Methods We measured the gene expression of VEGF ligands and their receptors in normal colorectal tissues (n=10), paracanceric tissues (n=14) and in colon cancer tissue (n=22), using seni-quantitative relative RT-PCR, together with the pattern of their expression by immunohistochemistry. Results (1) VBGF-A and VEGF-C significantly increased in carcinoma comparing with normal tissues; VEOF-D mRNA was significantly more abundant in normal tissues than in carcinoma. (2) A significantly greater amount of VEGF-A, VEGF-B, VEGF-C mRNA were present in carcinoma with metastasis than that without metastasis; while VEGF-D decreased in metastasis. (3) VEGFR-1 was significantly correlated with tumor grade, Duke's stage, and lymph node involvement; VEGFR-2 was with lymph node involvement;VEGFR-3 wash't correlated with any of the elinicopathologieal variables tested. Conclusion These resuits suggest that VEGF-A and VEGF-B play a role in tumor early development and VEGF-C plays a role in advanced disease, and is involved in metastasis with VEGF-D.
出处 《临床消化病杂志》 2006年第1期30-34,共5页 Chinese Journal of Clinical Gastroenterology
关键词 血管生成 VEGF配体 Angiogenesis VEGF ligand
  • 相关文献

参考文献16

  • 1NEUFELD G,COHEN T,GENGRINOVITCH S,et al.Vascular endothelial growth factor(VEGF)and its receptors[J],FASEB J,1999,13:9.
  • 2SENGER DR,GALLI ST,DVORAK AM,et al.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascited fiuid[J],Science,1984,219:983.
  • 3MAGLIONE D,GUERRIERO V,VIGLIETTO AM,et al.Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor[J],Proc Natl Acad Sci USA,1991,81:9267.
  • 4OLOFSSON B,PAJUSOLA K,KAIPAINEN A,ct al.Vascular endothelial growth factor B,a novel factor for endothelial cells[J].Proc Natl Acad Sci USA,1996,93:2576.
  • 5LEE J,GRAY A,YUAN J,et al.Vascular endothelial growth factor-related protein:A ligand and specific activactor of the tyrosine kinase receptor[J].Pro Natl Acad Sci USA,1996,93:1988.
  • 6ACHEN MG,TELTSCH M,KUKK E,et al.Vascular endothelial growth factor D(VEGF-D)is a ligand for tyrosine kinases VEGF receptor 2(Flk-1)and VEGF receptor 3(Flt-4)[J].Pro Natl Acad Sci USA,1998,95:548.
  • 7MEYER M,Clauss M,LEPPLE-WIENHUES A,et al.A novel vascular endothelial growth factor encoded of virus,VEGF-E,mediates angiogenesis via signaling through VEGFR-2(KDR)but not VEGFR-1(Flt-l)receptor tyrosine kinases[J].EMBO J,1999,18:363.
  • 8WALTENBERGER J,CLAESSON WL,SIEGHAHN A,et al.Different signal transduction properties of KDR end Flt-1,two receptor for vascular endothelial growth factor[J].J Biol Chem,1994,269:88.
  • 9GEORGE ML,TUTTON MC,JANSSEN F,et al.VEGF-A,VEGF-C and VEOF-D in colorectal cancer progression[J].Neoplasia,2001,3:420.
  • 10MEDA K,CHUNG YS,OGAWA Y,et al.Prognostic value of vascular endothelial growth factor expression in gastric carcinoma[J].Cancer,1996,77:858.

同被引文献35

  • 1彭佳萍,张苏展,韩明勇,郑树.VEGF和MVD在大肠癌组织中的表达及其临床意义[J].中国肿瘤临床,2004,31(21):1244-1245. 被引量:5
  • 2冼沛中,康旭,王芳.Survivin在大肠癌中的表达及其与血管生长因子的相关性研究[J].中国实验诊断学,2005,9(2):216-219. 被引量:7
  • 3罗小江,曾庆黎,刘勇.VEGF在大肠癌中的表达及意义[J].实用中西医结合临床,2005,5(6):7-8. 被引量:5
  • 4Robert R Jr.Vascular endothelial growth factor(VEGF)signaling in tumor progression[J].Crit Rev Oncol Hematol,2007,62(3):179-213.
  • 5Jenab-Woleott J,Giantonio BJ.Bevacizumab:Current indications and future development for management of solid tumors[J].Expert Opin Biol Ther,2009,9(4):507.
  • 6Jain R.kDuda DG,Clark JW,et al.Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer[J].Nat Clin Pract Oncol,2006,3(1):24-40.
  • 7Ribatti D.The crucial role of vascular permeability factor vascular endothelial growth factor in angiogenesis:a historical review[J].Br J Haematol,2005,128(3):303-309.
  • 8Yla-hertuala S,Martin JF.Cardio vascular gene therapy[J].Lancet,2000,355(91/99):213-222.
  • 9Nngy JA,Benjamin L,Zeng H,el al.Vascular permeability,vascular hyperpermeability and angiogenesis[J].Angiogenesis,2008,11(2):109-119.
  • 10Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor and angiogenesis[J].J Clin Oncol,2005,23(5):1011.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部